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Resistance to antibacterial agents has increased among many species of bacterial patho-
gens in the last two decades. While this has been recognized and has been a matter of
concern among those concerned with infectious diseases, it is only relatively recently that
prescribing physicians have become aware of the problem. A range of ofﬁcial bodies, both
national and international, have proposed a range of strategies for controlling this
increase in resistance. The relationship between resistance and clinical efﬁcacy or failure
is unclear in many areas, although increasingly resistance can be seen to be associated
with a less than optimal clinical response. Although the relationship between antibiotic
use and resistance is complex, there is an assumption that excessive use of antibacterials
may drive an increase in resistance. The term ‘prudent prescribing’ is frequently used in
ofﬁcial documents, but it is not easy for the prescriber to determine exactly what is
prudent prescribing. There have been efforts to reduce the unnecessary use of anti-
bacterials in the treatment of many community respiratory infections where the etiolo-
gical agent is likely to be viral. Guidelines for prescribing have been drawn up by
governments and professional societies but their impact can be variable. They need to
take account of the changing patterns of resistance, for example the rise in high-level
penicillin resistance among pneumococci. They also need to be readily accessible to the
practicing clinician. Surveillance systems are available in abundance and these may be
local, national, or international. They often, however, suffer from drawbacks and are
frequently selective. Frequently the prescriber does not have ready access to the most
appropriate data. Integrated strategies to control resistance are urgently needed, as are
improved rapid diagnostic facilities.
INTRODUCTION
The growth of resistance among bacterial patho-
gens to an ever widening spectrum of antimicro-
bials has caused concern among microbiologists
and infectious disease specialists for a couple of
decades, but has had less impact on prescribing
physicians until recently. Over the last 5–10 years,
however, there has been emerging concern at
various levels with regard to the issue of resistance
to antimicrobials and which strategy to implement
in order to manage this threat. This has now gone
beyond the responsibilities of knowledgeable pro-
fessionals within infectious diseases and micro-
biology and has become an issue of both political
and public concern. Various international
approaches have been developed, many of which
are reﬂected in national strategies.
At governmental level, the approach taken can
have an impact on funding for research and the
delivery of health-care systems. National and
international health-care agencies have become
involved, as well as various professional societies
specializing in infectious diseases and a range of
specialists in infection. In addition, licensing agen-
cies, pharmaceutical companies and the prescri-
bers themselves are increasingly involved. In more
recent years, the general public has also become
aware of the problem and concern has spread.
Over the past few years a number of ofﬁcial
bodies, including some of the highest authorities,
have been involved in investigating, reporting on
and advising their governments on the strategy
necessary to control the increase in resistance to
antimicrobial agents (see Table 1). In the USA a
Task Force was set up in 1995 jointly by the Senate
and the American Society for Microbiology (ASM)
[1] and this was followed in 2000 by the ‘Public
Health Action Plan to Combat Antimicrobial
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Resistance’ issued jointly by the Centers for Dis-
ease Control (CDC), the Food and Drug Admin-
istration (FDA)andtheNational InstitutesofHealth
(NIH) [2]. In the UK the House of Lords Select
Committee on Science and Technology issued a
report in 1998 [3] on ‘Resistance to antibiotics and
other antimicrobial agents’. Following the publi-
cation of this report the Department of Health
(DH) has issued a UK antimicrobial resistance
strategy and action plan [4]. Also in the UK the
Standing Medical Advisory Committee (SMAC)
was asked in July 1997 to examine the issue of
antimicrobial resistance in relation to medical pre-
scribing. An interdisciplinary subgroup was con-
vened and they presented a report in 1999 entitled
‘The Path of Least Resistance’ [5].Most recently the
Specialist Advisory Committee on Antimicrobial
Resistance (SACAR) has been established to ad-
vise government on all components relevant to
resistance, including clinical prescribing, public
education and surveillance. In the European
Union there have been a number of pivotal con-
ferences organized by the Scientiﬁc Steering Com-
mittee (SSC). One of these, for example, was held
in Copenhagen in 1998 and resulted in the docu-
ment entitled ‘The Microbial Threat’. This was
followed by one in Visby in 2001 and also in
Brussels in 2001 [6]. The World Health Organiza-
tion (WHO) has also addressed the problem and
issued a document entitled ‘WHO Global Strategy
for Containment of Antimicrobial Resistance’ [7].
CAN THE CLINICIAN RECOGNIZE
AN ANTIBIOTIC-RESISTANT
INFECTION?
Critical to the control of antibiotic resistance is the
recognition of its clinical impact. In the hospital
environment the clinician has the beneﬁt of diag-
nostic microbiological laboratories and advice is
readily available. Such clinicians are thus more
likely to be aware of how resistance can complicate
therapy. Two examples are described which on
appropriate investigation led to the recognition of
drug-resistant infections. In an Italian hospital
seven patients from different wards were found
to be infected with a carbapenem-resistant strain
of Pseudomonas aeruginosa [8]. The strainwas found
to produce a novel metallo-b-lactamase (VIM-1)
similar to one originally reported from the Far East
(IMP-1) and not, until this study, found in other
parts of the world. This b-lactamase conferred
high-level resistance to imipenem [minimum inhi-
bitory concentration (MIC) >128mg/L] and to
other broad spectrum b-lactam antibiotics, includ-
ing meropenem (MIC 128mg/L), ceftriaxone
and ceftazidime (MIC >128mg/L), piperacillin/
tazobactam and ticarcillin/clavulanate (MIC
>128mg/L). Poor activity was also seen for a
range of other antibacterial agents; ciproﬂoxacin
(MIC>128mg/L), amikacin and tobramycin (MIC
32–128mg/L).
Most of the patients (six of the seven) had been
admitted to the intensive care unit at some time
during their stay in hospital and all had serious
underlying conditions. In the intensive care unit
the patients were not housed in individual wards
and this may have contributed to the spread of the
organism. Five of the seven patients died and the
authors emphasize the importance of early recog-
nition of such strains.
In a prospective study of neutropenic patients
with cancer, 485 episodes of bacteremia occurred
and of these 88 (18%) were caused by viridans
streptococci [9]. Ten of these cases were associated
with serious complications (acute respiratory
Table 1 Major bodies discussing the problems of resistance to antimicrobials
Official body Title of document Date of report
European Union The Microbial Threat
(SSC) —Copenhagen 1998
—Visby 2001
—Brussels 2001
UK
House of Lords Select Committee Resistance to antibiotics and other antimicrobial agents 1998
Department of Health Antimicrobial resistance strategy and action plan 2001
SMAC The Path of Least Resistance 1997
USA—Senate and ASM Task force on microbial resistance 1995
FDA/CDC/NIH Public-Health Action Plan to combat antimicrobial resistance 2000
WHO Global Strategy for containment of antimicrobial resistance 2000
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distress syndrome and/or septic shock) and eight
of these patients died, twowith fulminating infect-
ion. Viridans streptococci are normally suscepti-
ble to penicillins, but four of these isolates (all
Streptococcus mitis) had diminished susceptibility,
the penicillin MIC values being between 0.25 and
4mg/L. In addition, ﬁve of the isolates were resist-
ant to ceftazidime which had MIC values of
between 2 and 32mg/L (four S. mitis and one S.
salivarius). It can thus be seen that careful analysis
of microbiological data and clinical outcomes will
deﬁne the impact of antibiotic resistance on patient
management.
THE WIDER IMPACT OF
RESISTANCE
Methicillin-resistant Staphylococcus aureus
Methicillin-resistant Staphylococcus aureus (MRSA)
strains have become a major problem in many
countries, both afﬂuent and poor [10]. The preva-
lence varies markedly from country to country
with very high levels (60% of S. aureus isolates)
being reported from the Far East [11] but far lower
levels from other countries such as Germany 5.5%,
The Netherlands 1.5%, and Switzerland 1.8% [12].
In the UK (see Figure 1) the percentage of cases of
S. aureus bacteremias caused by MRSA was re-
ported at the end of 2001 to be between 34 and
51% in different areas, with an overall prevalence
of 42% [13].
Until recently, MRSA were restricted to hos-
pitals, but increasingly they are now found in
the community. The deﬁnition of ‘community-
acquired’ MRSA used by Naimi et al. [14] was
that of an infection with a culture positive for
MRSA in a patient who was either an outpatient
or had not had any record of surgery, renal dia-
lysis, hospitalization, or residence in a long-term
care facility (all risk factors for acquiring MRSA)
for 1 year preceding the culture of anMRSA. Other
known risk factors for the acquisition of MRSA
include users of injectable drugs and subjects with
indwelling catheters or other medical devices.
These authors reviewed the record ofMRSA infect-
ions from hospitals in Minnesota between 1996
and 1998 and of the 4302 isolates of S. aureus
during this period, 856 (19.9%) were MRSA. Of
the MRSA isolates, using the above deﬁnition, 354
(41.4%) were acquired in the community [14].
Community-acquiredMRSA are often notmulti-
resistant epidemic strains but are susceptible to a
range of antibiotics other than b-lactams, never-
theless they can still be highly pathogenic and can
cause fatal infections. Four fatal infections
occurred in children in the USA between 1997
and 1999 [15] (see Table 2). These children had
no established risk factors and their isolates were
susceptible to a wide range of non-b-lactam
antibacterials but all were treated initially with
cephalosporins. The editorial emphasizes the
importance of being aware of the possibility of
MRSA in areas where it is known to be present in
the community and of the importance of obtaining
cultures as soon as possible.
As a follow up to this report, Groom et al. [16]
reviewed the records of patients from anAmerican
Indian Health Service facility in the rural mid-west
USA who had had a staphylococcal infection
conﬁrmed by laboratory culture. Out of a total
of 112 isolates of S. aureus 55% (62) were MRSA
and of these 74% (46) were community-acquired.
There were no obvious risk factors for the acquisi-
tion of these strains. A high percentage were
related clones and were not related to those pre-
vailing in local hospitals.
Acquisition of MRSA from the community has
been found to be much lower in many other
Figure 1 Bacteremias caused by methicillin-resistant Sta-
phylococcus aureus (MRSA) as a percentage of all Staphylo-
coccus aureus infections (England and Wales, 2001).
Reproduced by permission of CDR Weekly.
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studies. In a survey of healthy children attending a
pediatric, inner city, outpatient clinic in Chicago
(USA) 24.4% of the children were found to be
colonized asymptomatically with S. aureus, but
only 2.5% of the isolates were MRSA [17]. In a
study of older people (aged over 65 years) in the
UK with no known risk factors the prevalence of
carriage of MRSA was found to be low, 8 per 1000
population. The isolates were, however, all of the
epidemic strain that was circulating in the local
hospitals at the time of the study [18].
The prevalence of MRSA that has been acquired
in the community thus appears to vary as much as
the prevalence of MRSA in the hospital environ-
ment. Chambers [19] has suggested that the pre-
valence of MRSA in the community will inevitably
increase with time, mirroring the growth of MRSA
in hospitals over the past two decades.
The pneumococcus
The reduction in susceptibility to penicillins
among Streptococcus pneumoniae is well known
and has been linked to the usage of penicillins
or of oral cephalosporins [20,21]. Although this is a
global problem, there are marked variations in the
proportion of strains of pneumococci that are
resistant in different countries. A recent survey
in the Alexander Project showed that the percen-
tage of strains fully resistant andwith intermediate
resistance to penicillins ranged from below 10% in
Belgium, Italy, Germany and The Netherlands [22]
to over 50% in France, Japan, Mexico and Saudi
Arabia, with 60% resistance in Hong Kong (see
Table 3). A feature revealed in recent surveys is the
increase in pneumococci with full resistance to
penicillins. In some countries, such as France,
Hong Kong, the Irish Republic, Japan and the
USA, full resistance is now more common than
intermediate resistance.
This decrease in the susceptibility of pneu-
mococci to penicillins has had an impact on
the clinical management of infections where
Table 2 Four fatal cases of community-acquired methicillin-resistant Staphylococcus aureus infections in children
Case
Number Age Syndrome Antimicrobial susceptibility
1 7 years septic arthritis
sepsis
pneumonia/empyema
trimethoprim/sulfamethoxazole
tetracycline ciprofloxacin, gentamicin,
erythromycin, clindamycin, vancomycin
2 16months severe sepsis trimethoprim/sulfamethoxazole
tetracycline ciprofloxacin,
gentamicin, erythromycin,
clindamycin, vancomycin
3 13 years necrotizing pneumonia
severe sepsis
trimethoprim/sulfamethoxazole
ciprofloxacin, gentamicin, erythromycin,
clindamycin, vancomycin
4 12months necrotizing pneumonia
severe sepsis
trimethoprim/sulfamethoxazole
tetracycline ciprofloxacin, gentamicin,
erythromycin, clindamycin, vancomycin
Adapted from MMWR [15].
Table 3 Prevalence of penicillin resistance in various
countries
Strains resistant to penicillin (%)
Country Intermediate
Full
resistance
Total
resistance
Austria 7.6 4.8 12.4
Belgium 3.0 5.0 8.0
Brazil 14.3 0.0 14.3
France 12.6 40.7 53.3
Germany 5.4 1.8 7.2
Greece 16.4 15.2 33.6
Hong Kong 0.0 60.0 60.0
Irish Republic 7.3 25.5 32.8
Italy 6.0 3.0 9.0
Japan 23.3 24.3 47.6
Mexico 21.4 28.6 50.0
The Netherlands 3.2 0.0 3.2
Saudi Arabia 50.0 28.6 78.6
Singapore 13.9 16.7 30.6
South Africa 36.3 15.4 51.7
USA 14.0 22.2 36.2
Alexander Data 1998–European figures adapted from
Schito et al. [22]; rest of the world figures from Glaxo
SmithKline data on file; publication in preparation.
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S. pneumoniae is the most likely etiological agent. In
some countries this has led to a change in the choice
of antimicrobial agent and this in itself could have
contributed to resistance in other agents.
WHAT EVIDENCE IS THERE THAT
RESISTANCE IN VITRO LEADS
TO CLINICAL FAILURE?
There is a dilemma in reconciling the laboratory
ﬁndings of susceptibility or resistance and the res-
ponse to therapy. In some infections resistance to
the causative pathogen can be shown to inﬂuence
the clinical response. Ball [23] has summarized a
number of studies in otitis media. Amoxicillin and
ceftriaxone have both shown good clinical efﬁcacy
in cases where the infecting strain is of inter-
mediate resistance to penicillin, which correlates
well with the pharmacodynamic predictions for
the relative time that inhibitory concentrations
remain above the MIC [24]. In other studies of
otitis media, the clinical response rate to treatment
with amoxicillin/clavulanic acid was 89% (56/63)
when the organism was fully sensitive to penicil-
lins. In contrast, when the organism was fully
resistant to penicillins, the response rate was only
77% (7/9) [25] (see Table 4). These authors also
noted a poorer response at follow-up in patients
infected with a resistant pneumococcal strain.
A study in infants under 18months of age who
were treated with an oral cephalosporin (cefurox-
ime axetil or cefaclor) resulted in a bacteriological
failure rate of 58% in the cefaclor group and 21% in
the cefuroxime groupwhen the infecting strainwas
penicillin-resistant but only 6% when the strain
was susceptible [26]. These authors correlated the
cephalosporin MIC more closely with bacterial
eradication and showed that an MIC >0.5mg/L
was associated with failure to eradicate the organ-
ism. There was also a higher rate of clinical failure
in patients in whom the infecting organism had
not been eradicated [26] (see Table 4).
Barry et al. [27] found that infants (aged up to
18months) with acute pneumococcal otitis media
treated with b-lactams were more likely to fail to
respond if their infecting strain was of reduced
susceptibility to penicillin (see Table 4). The same
group, Gehanno et al. [28] related the MIC of
penicillin and cefuroxime against the pneumo-
coccal strain with the clinical success rate in 84
children treated with cefuroxime axetil. Of the
84 pneumococcal isolates, 42 had reduced
susceptibility to penicillin and 38 of these isolates
were fully resistant. Although the MIC values of
cefuroxime were slightly higher than those of
penicillin, the overall correlation was similar.
The success rate was high for both penicillin/
cefuroxime susceptible and intermediate strains
(92.9% if the penicillin MIC was used and 93.5%
if the cefuroxime MIC was used), but when the
MIC rose above 1mg/L for either compound, the
success rate was reduced to 78.6% (29/38 patients)
(see Table 4).
An earlier study of pneumococcal pneumonia in
adults by Pallares et al. [29] found a 6% increase in
the mortality rate in patients infected with pneu-
mococcal strains with reduced susceptibility to
penicillin compared with those infected with peni-
cillin-susceptible strains. This difference was not
statistically signiﬁcant, but the overall mortality
rate in those with penicillin-resistant infections
was 14% higher and Ball [23] points out that
although this study has frequently been quoted
as justiﬁcation for continuing to use b-lactams,
notwithstanding the lack of statistical signiﬁcance,
he questions their use in higher risk patents. In
addition the study was carried out between 1984
and 1993 when there were fewer strains with high-
level resistance to penicillins (anMIC of equal to or
above 2mg/L), and with the current increase in
the prevalence of these strains, doubt is cast on the
value of b-lactams in severely ill patients infected
with such strains.
Table 4 Association between penicillin susceptibilty and
effect of b-lactams in otitis media infections caused by
Streptococcus pneumoniae
Penicillin susceptibility
of infecting strain
(no. cured/no. treated)
Ref. Treatment Resistant Susceptible
[27] oral cephalosporins 44/54
(81%)
152/166
(92%)
[28] cefuroxime axetil 29/38
(76.3%)
39/42
(92.9%)
[25] amoxicillin/clavulanate 7/9
(77%)
56/63
(98%)
[26] cefaclor 7/12a
(58%)
–
–
cefuroxime axetil 4/19a
(21%)
3/47a
(6%)
P¼ 0.03.
aNumbers of patients with bacteria eradicated/numbers
treated.
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With macrolides, the clinical evidence is also
conﬂicting, but in some studies a poorer clinical
response tomacrolides (erythromycin, clarithromy-
cin, azithromycin, or josamycin) was seenwhen the
infecting strain of S. pneumoniae was resistant to
erythromycin [30]. This study was carried out in
one hospital in Spain and three in the USA. Patients
with pneumococcal bacteremia were selected, 141
who were infected with a macrolide-susceptible
strain and 86 who were infected with a macrolide-
resistant strain. In the group infected with a macro-
lide-susceptiblepneumococcus, nonewas receiving
macrolide therapy, but of those who were infected
with a macrolide-resistant strain, 22% (19/86) were
being treatedwith amacrolide at the timewhen the
bloodsamplewascollected.Thisdifferenceishighly
signiﬁcant, P¼<0.001.
Themajority of the isolates fromSpanish patients
(10/11) were of the MLSB phenotype (these strains
have high level resistance to all macrolides and the
related lincosamides and streptogramin B) and car-
ried the erm gene which codes for high-level resist-
ance. In contrast the majority of the isolates from
American patients (six of eight) were of the M
phenotype and/or carried the mef gene [30]. This
type of resistance is caused by efﬂux and strains are
usually less resistant.MICs of erythromycin ranged
from 4mg/L against some of the Mstrains to
>128mg/L against theMLSB strains. These authors
suggest that the use of macrolides as empiric ﬁrst-
line treatment for community-acquired infections
should be reconsidered.
HOW CAN THE PRESCRIBING
PHYSICIAN INTERPRET THESE
FINDINGS?
The dilemma evident in the various publications is
illustrated by the comments from the Infectious
Diseases Society of America (IDSA) in their treat-
ment guidelines for community-acquired pneu-
monia, published in 1998,
‘Members of the panel are not aware of clinical
failures of penicillin treatment for pneumococcal
pneumonia that have been ascribed to in vitro
resistance, and one report has shown a lack of
clinical correlation with in vitro susceptibility test
results for patients treated with penicillin or
cephalosporins’ [31].
This last comment refers to the Pallares publica-
tion of 1995 [29]. Such comments could lead some
to question whether there is a difference between
an ‘antibiotic-resistant organism’ and an ‘anti-
biotic-resistant disease’.
Some of these problems arise because of the
deﬁnitions of ‘resistance’ both in vitro and clini-
cally. The purposes of in vitro susceptibility testing
are many and can confuse the situation when
trying to interpret clinical relevance of the results.
Clinical deﬁnitions of resistance are also complex.
It is not clear what level of in vitro resistance
affects outcome. It is probable that the inﬂuence
of the MIC will vary with the type of resistance,
the disease, and the organism [32]. A later edition
of the IDSA Guidelines published in 2000 [33]
states,
‘...that from a clinical point of view, the MIC has
entirely different meaning, depending on the
infection being treated. A strain with reduced
susceptibility (e.g. MIC, 0.5 mg/mL) behaves as a
susceptible organism when it causes pneumonia
but probably not when it causes meningitis’.
It is of note that these IDSA Guidelines have
changed between 1998 and 2000, no doubt a reﬂec-
tion of the continued growth in penicillin resis-
tance and the increase in the proportion of strains
now having high-level resistance. The 2000 Guide-
lines [33] contain the statement that
‘Recommendations for treating patients who
require empiric antibiotic selection are based on
severity of illness, pathogen probabilities, resis-
tance patterns of S. pneumoniae (the most
commonly implicated etiologic agent), and co-
morbid conditions.’
Table 5 The rate of penicillin resistance in pneumococci in
30 UK centers (total number isolates 1040)
Strains resistant to penicillin (%)
Center Intermediatea High-levelb Total
Combined results 3.3 3.3 6.6
Belfast Hospital A 15.4 30.8 46.2
Belfast Hospital B 5.5 5.0 6.0
Birmingham 5.0 17.5 22.5
Dudley 10.0 2.5 12.5
Leicester 0.0 0.0 0.0
Sheffield 0.0 0.0 0.0
Southampton 11.1 0.0 11.1
aIntermediate resistance ¼ penicillin MIC 0.12–1mg/L.
bHigh-level resistance ¼ penicillin MIC >1mg/L.
Adapted from Wise & Andrews [35].
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They also now seem to accept that resistance in
pneumococci may be important and state
‘. . .in treating pneumonia with generally accepted
doses of penicillins, . . . resistance may be
important, especially if it is high-grade (e.g.
MIC, >4 mg/mL)’.
Surveillance data are valuable for epidemio-
logical purposes but since there is no control of
the denominator and the samples are of necessity
highly selective, they have to be interpreted with
great caution [34]. They are retrospective and
rarely sufﬁciently local for a clinician to use them
as guidance. This latter point was highlighted by
Wise & Andrews [35] who showed the wide regio-
nal variation in resistance to penicillin in pneumo-
cocci from various UK hospitals. Clearly the
overall combined resistance rate of 6.6% total
penicillin resistance would have little relevance
for a clinician in the Belfast hospital with total
resistance rate of 46.2% or to the Birmingham
hospital with a high-level resistance rate of
17.5%. Similarly in the areas with no resistance
reported, such combined data would also be of
little value (see Table 5).
In addition, surveillance data are very rarely
linked to disease outcome. These data can, how-
ever, be more precise if, for example, the resistance
mechanism has a genetic basis it may be linked to a
clear contraindication for the use of a particular
drug. The new science of pharmacodynamics has
given a valuable insight into the importance of the
relationship between the penetration of the drug to
the various body compartments and the location of
the infecting organism. Studies by Craig & Andes
[24] have indicated that the distribution of both
ceftriaxone and amoxicillin at clinical doses into
respiratory tissues should provide levels that are
inhibitory to most strains of pneumococci with
intermediate resistance, but probably not for
strains with high resistance.
With S. pneumoniae, the perception is that inter-
mediate resistance to penicillin and low-level
resistance to macrolides have little impact on the
clinical outcome but that high-level resistance to
both b-lactams and macrolides may have an
impact. As has been illustrated, there is still a
paucity of good studies to back up such beliefs,
although more evidence is gradually accumulat-
ing [32]. Most clinicians’ interpretation of suscept-
ibility data is affected by the disease in question. I
would, for example, be reluctant to use a drug to
treat meningitis if there were reports of a rate of
resistance among the likely infecting organisms of
over 1%. In contrast, in treating a community-
acquired urinary tract infection, higher levels of
resistance may be acceptable. Overall, this often
leaves the prescribing physician in a dilemma.
WHAT CAN BE DONE TO REDUCE
OR CONTROL RESISTANCE?
Various government and international strategies
have been designed to contribute towards control-
ling or reducing the increase in resistance, but do
they fulﬁl these aims? Two important aspects
emphasized in all of them are surveillance of
microbial resistance and monitoring of drug use.
These two actions need to be linked closely so that
any impact of an increase in use of a particular
agent and a rise in resistance to it can be detected
rapidly. Education, both of the public and a range
of professionals has also been emphasized in the
various documents. ‘Prudent’ prescribing is
Figure 2 Advertisement used by UK Department of
Health. Reproduced by permission of UK Department of
Health.
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deemed essential both in the community and in the
hospital and infection control and hygiene are
essential in hospitals to control and prevent the
spread of resistant strains. Person-to-person
spread has been shown to play a major role in
the spread of MRSA in hospitals [36,37]. Good
basic hygiene, in particular handwashing and
the wearing of gloves by the nursing and medical
staff, can limit the spread of endemic strains, but
often isolation of patients known to be carrying
MRSA is required. If an outbreak occurs, especial-
ly of an epidemic strain, far more stringent mea-
sures may be required to contain the spread [38].
In the UK during the winter of 1999–2000 there
was a major publicity campaign to persuade the
public that antibiotics are unnecessary for treating
upper respiratory tract infections since these are
mainly viral, not bacterial, in origin. This included
a number of posters (see Figure 2 for example),
which were displayed prominently in general
practice surgeries, and a website [39] which was
available to the general public. Following this
campaign, there was a drop in the prescribing rate
of oral antibacterials and thus the campaign could
be regarded as a success.
An interesting point, however, is that at the
same time there was an increase in the numbers
of prescriptions for intravenous macrolides in
hospital infections. What is unknown is whether
there was a link between this and the reduction of
the community use. Could a reduction in prescrib-
ing antibacterials result in some patients being
admitted to hospital who would have previously
been managed successfully in the community?
The term ‘prudent prescribing’ has been used in
a number of UK Government initiatives and has
been deﬁned by the Department of Health as
follows:
‘The use of antimicrobials in the most appropriate
way for the treatment or prevention of human
infectious diseases, having regard to the diagnosis
(or presumed diagnosis), evidence of clinical
effectiveness, likely benefits, safety, cost (in
comparison with alternative choices), and pro-
pensity for the emergence of resistance. The most
appropriate way implies that the choice of route,
dose, frequency and duration of administration
have been rigorously determined.’
This is a council of excellence, but to be able to
fulﬁl all of these criteria is rare, especially in the
management of community-acquired infections.
For many clinical diagnoses the etiological agent
cannot be predicted accurately, with a few excep-
tions such as erysipelas, anthrax and meningo-
coccemia. Microbiological diagnosis for infections
in the community is rarely available at the time of
prescribing and is often not available at all, with
empiric therapy being common. In addition, the
etiology of many community-acquired infections,
such as respiratory tract and urinary tract infect-
ions, may be variable or even mixed.
With regard to deciding what is a ‘correct’ dose
and the appropriate frequency and duration of
therapy, these also, with rare exceptions, are not
precise factors. The exceptions include pulmonary
tuberculosis, gonorrhea and endocarditis, where
there are good guidelines for precise therapy.With
more common infections there are wide variat-
ions in these parameters and no good basis for
prescribing.
PRESCRIBING GUIDELINES
Various guidelines are now available for a number
of common infections although these can vary
between countries. The IDSA Guidelines for com-
munity-acquired pneumonia have been referred to
above and in the UK, the British Thoracic Society
have made recommendations for the treatment of
community-acquired pneumonia [40]. Canada
also has published guidelines for community-
acquired pneumonia and these have been com-
pared with the American guidelines by Mandell
[41] who points out how similar they are.
The British Thoracic Society Guidelines [40]
recommend amoxicillin or a macrolide given
orally for non-severe cases treated at home and
for hospitalized cases amoxicillin plus a macro-
lide, with a ﬂuoroquinolone as an alternative
(orally or intravenously). Fluoroquinolones are
not recommended for use in the community.
For serious cases in intensive care the recommen-
dations are co-amoxiclav and a macrolide with
or without rifampicin. The alternatives are a sec-
ond- or third-generation cephalosporin plus a
macrolide, or a ﬂuoroquinolone plus penicillin
G. These recommendations differ from those in
the American and Canadian guidelines in that
ﬂuoroquinolones are not recommended for com-
munity-managed, community-acquired pneumo-
nia. The North American Guidelines [31,33]
include an additional category of patients in the
intensive care unit where Pseudomonas is suspected
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as a causative agent—for such patients an
antipseudomonal b-lactam plus ciproﬂoxacin is
recommended.
TheBritish Thoracic SocietyGuidelines [40]were
drawn up after a thorough literature search asses-
sing the publications on the etiology of communi-
ty-acquired pneumonia. The survey found a total
of 57 papers dealing with the microbiology of
community-acquired pneumonia, covering com-
munity, hospital, or intensive care units, with a
total of 11 294 isolates overall, only 1039 of which
came from community infections (see Table 6). Of
the 12 studies in the UK, only one study was of
patients treated in the community and this
resulted in only 236 isolates (see Table 7). These
are very few results on which to base decisions;
this situation is similar to that in other countries
and illustrates the difﬁculties in getting precise
data to inform prescribing recommendations.
Although S. pneumoniae comes out of these sur-
veys as the most commonly occurring etiological
agent of pneumonia in the community, the British
Thoracic Society Guidelines do state
‘Recent data suggest that the importance of S.
pneumoniae infection is waning as the frequency
of newer pathogens such as Chlamydia pneu-
moniae and ‘non-penicillin responsive’ pathogens
such as the aerobic Gram-negative enteric bacilli
increase, including the Enterobacteriaceae and
Pseudomonas aeruginosa’.
THE VALUE OF THE GUIDELINES
FOR THE MANAGEMENT OF
DISEASE
How effective are the various guidelines? One can
review the literature in an attempt to assess the
Table 6 Analysis of the published data on the etiology of community-acquired pneumonia
Number of isolates
Country of study
Community
(8 studies)
Hospital
(36 studies)
ICU
(14 studies)
Totals
(57 studies)
UK 236 1137 185 1558
Europe (excluding UK) 654 6026 1148 7828
Australia and New Zealand – 453 – 453
North America 149 1306 – 1455
Total 1039 8922 1333 11294
Adapted from Thorax 2001 [40].
Table 7 Etiology of community-ac-
quired pneumonia in adults the UK
(figures are percentages of isolates)
Community
1 study
236 isolates
Hospital
5 studies
1137 isolates
ICU
4 studies
185 isolates
Streptococcus pneumoniae 36.0 39.0 21.6
Haemophilus influenzae 10.2 5.2 3.8
Legionella species 0.4 3.6 17.8
Staphylococcus aureus 0.8 1.9 8.7
Moraxella catarrhalis NR 1.9 NR
Mycoplasma pneumoniae 1.3 10.8 2.7
Chlamydia pneumoniae NR 13.1 NR
Chlamydia psittaci 1.3 2.6 2.2
Chlamydia burnetii 0.0 1.2 0.0
Gram-negative enteric
bacilli
1.3 1.0 1.6
Viral – all viruses 13.1 12.8 9.7
Influenza A and B 8.1 10.7 5.4
Mixed 11.0 14.2 6.0
Other 1.7 2.0 4.9
None detected 45.3 30.8 32.4
NR¼not reported.
Adapted from Thorax 2001 [40].
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value of certain guidelines but frequently their
effectiveness has been assessed on a cost basis
and while this may be accurate for the particular
health care center in which the study was per-
formed, it may not hold true for health-care
systems where many medical practices may be
different [42].
Another important area is whether these guide-
lines assist in preventing the development of resist-
ance. The evidence for this is sparse and is rarely
even assessed [43]. Outcome-related data with
regard to resistant organisms are urgently needed.
The data sheets on drugs give guidance on the
use of that drug and in the EU this is controlled by
the Committee on ProprietaryMedicinal Products.
These include a great deal of useful information,
such as the general properties, mode of action and
class of the drug, the breakpoints for susceptible,
intermediate and resistant organisms, and the
pathogens likely to be inhibited in Europe. The
range of susceptibilities has to be updated every
5 years. Unfortunately some of this information is
so general and of such awide range as to be of little
help. An example is provided by the information
on erythromycin where the range of resistance to
erythromycin in strains of Streptococcus pyogenes is
stated to be 2–40% and that for S. pneumoniae to be
0–40%. At a local level, with no knowledge of the
expected range of susceptibility in that area, these
ﬁgures are not helpful.
Even when the information comes from a man-
ufacturer’s own data sheet it is not always con-
sistent. There are examples of differences between
the recommended doses and length of therapy for
the same drug and the same disease in different
countries. Some of these differences can be sub-
stantial, with the length of recommended treat-
ment varying from 7 to 14 days and the dose
varying from 250mg to 500mg for selected agents
such as a macrolide. This indicates that the ‘most
appropriate dose’ is not always apparent.
DIAGNOSIS
In the community, diagnosis is mostly clinical and
treatment is mostly empiric. Although diagnostic
facilities are available, there are problems with
their use, one of the most important being the time
between collecting a sample, sending it off to the
laboratory and receiving a result. Inevitably this
delaywill mean that the result has a limited impact
on therapy, since empiric therapy has already been
initiated. For the community physician there is a
lack of user-friendly, up-to-date information on
trends in susceptibility. In addition there are prob-
lems of quality control and standardization to
consider.
Rapid diagnostic tests could be a way forward,
with many advantages for the community as well
as for hospital medicine. For example, techniques
that can identify organisms or distinguish viral
from bacterial infections at the initial consultation
could improve disease management. They might
also identify certain potentially critical diseases,
such as meningitis, endocarditis and sepsis syn-
drome. Colonizing organisms, hopefully, could be
distinguished from pathogenic strains. Were such
techniques available, they would help guide the
therapeutic choice, reduce the costs of managing
the infection, and, of prime importance, minimize
the risks of selecting resistant strains.
CONCLUSIONS
The prescribing clinician is in a dilemma. He feels
responsible for the problem of resistance and yet is
rarely presented with robust tools to bring about
its control. It is therefore essential that strategies to
control resistance are integrated and tested scien-
tiﬁcally to ensure that prescribing is supported
more effectively. The goal must be cost-effective
prescribing whilst minimizing the risks of adding
to the burden of antibiotic resistance.
The most urgent needs include validated stu-
dies to deﬁne the optimum choice, dose and dura-
tion of therapy for a wide range of common
infections, especially for community infections;
this would enable prescribing to be ‘prudent’.
Currently this information is not available. Sur-
veillance data to support prescribing practice need
to be locally generated and to be not just organism-
based but disease-focused as well. They should
also be linked to outcome measurements. Rapid
diagnostic facilities that are ‘near-patient’ and
clinically relevant should be developed and made
widely available. The key to success with many of
these developments is effective and timely inform-
ation-technology-based support systems to allow
links between surveillance and patient outcome.
These would be continuously updated as informa-
tion became available allowing treatment to be
audited and reﬁned, and ensuring that it supports
the control of antibiotic resistance as well as
improving disease management.
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